CHANGES IN PLATELET SIZE INDUCED BY TREATMENT IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS. CYTOSKELETAL STUDY DURING PLATELET PRODUCTION

CELLUCCI AS; LEV PR; YANUK D; GOETTE N,; GLEMBOTSKY AC; DE LUCA G; LIRA MC; BARONI PIETO MC; HELLER PG; MARTA RF

Congreso; 2023 Cell Biology of Megakaryocytes and Platelets Gordon Research Conference; 2023

Myeloproliferative Neoplasms (MPN), comprising essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (MF) are associated to thrombosis. Available therapeutic tools include hydroxyurea (HU), α-Interferon (α-IFN), anagrelide (ANA) and ruxolitinib (Ruxo), a JAK inhibitor mainly used in MF. Considering that large platelets are more reactive and were associated to thrombotic events in a number of pathological conditions, we evaluated the Maximum Platelet Diameter (MPD) in a group of 76 patients with MPN, according to the diagnosis (ET, 36; PV, 16; MF, 24), type of mutation (JAK2V617F, 51; MPL, 1; CALR, 18, triple negative, 3) and treatment (without treatment, 26; HU, 23; ANA, 10; α-IFN, 8; Ruxo, 9). MPD was measured as follows: blood smears were stained with May-Grumwald Giemsa and representative pictures of at least 100 platelets/sample were taken using an optical microscope with a 100 x oil immersion objective. MPD was obtained using a cellular analysis software (VideoTesT-Master Morphology, St. Petersburg, Russia). MPN patients showed increased MPD (p